Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Burning Rock Biotech (BNR) EBITDA: 2019-2024

Historic EBITDA for Burning Rock Biotech (BNR) over the last 6 years, with Dec 2024 value amounting to -$47.0 million.

  • Burning Rock Biotech's EBITDA rose 417.23% to $17.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.1 million, marking a year-over-year decrease of 117.64%. This contributed to the annual value of -$47.0 million for FY2024, which is 48.61% up from last year.
  • Per Burning Rock Biotech's latest filing, its EBITDA stood at -$47.0 million for FY2024, which was up 48.61% from -$91.5 million recorded in FY2023.
  • In the past 5 years, Burning Rock Biotech's EBITDA ranged from a high of -$47.0 million in FY2024 and a low of -$134.8 million during FY2022.
  • Moreover, its 3-year median value for EBITDA was -$91.5 million (2023), whereas its average is -$91.1 million.
  • In the last 5 years, Burning Rock Biotech's EBITDA crashed by 326.14% in 2020 and then soared by 48.61% in 2024.
  • Over the past 5 years, Burning Rock Biotech's EBITDA (Yearly) stood at -$89.5 million in 2020, then slumped by 46.58% to -$131.2 million in 2021, then declined by 2.75% to -$134.8 million in 2022, then skyrocketed by 32.15% to -$91.5 million in 2023, then spiked by 48.61% to -$47.0 million in 2024.